

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 April 2007 (26.04.2007)

PCT

(10) International Publication Number
WO 2007/045477 A3

(51) International Patent Classification:

C07K 16/00 (2006.01) A61K 39/395 (2006.01)
C07K 16/24 (2006.01)

(21) International Application Number:

PCT/EP2006/010098

(22) International Filing Date: 19 October 2006 (19.10.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0521509.0 21 October 2005 (21.10.2005) GB
0616666.4 22 August 2006 (22.08.2006) GB

(71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CAMPBELL, Emma, Michelle** [GB/GB]; Novartis Horsham Research Centre, Wimplehurst Road, Horsham, West Sussex RH12 5AB (GB). **PARVEEN, Sofia** [GB/GB]; Novartis Horsham Research Centre, Wimplehurst Road, Horsham, West Sussex RH12 5AB (GB). **BUECHLER, Joe** [US/US]; 1343 Cassins Street, Carlsbad, CA 92011 (US). **VALKIRS, Gunars** [US/US]; 2893 Paseo del Sol, Escondido, CA 92025 (US).

(74) Agent: **HILLEBRAND, Dirk**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report

(88) Date of publication of the international search report:
21 June 2007

(48) Date of publication of this corrected version:
2 May 2008

(15) Information about Correction:
see Notice of 2 May 2008

(54) Title: HUMAN ANTIBODIES AGAINST IL-13 AND THERAPEUTIC USES

(57) Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.



WO 2007/045477 A3